Incyte Corporation (INCY) Net Income
The trailing-twelve-month (TTM) net income for Incyte Corporation (INCY) is $1.43 Billion with a year-over-year change of +6631.44%. Net income represents the company's bottom line profit after all expenses, taxes, and interest.
INCY Annual Net Income
Net Income (TTM)
$1.43B
$1.43 Billion
Year-over-Year Change
+6631.44%
vs. $21.27M a year ago (TTM)
Net Income CAGR
+24.51%
5 Year compound annual growth rate
Net Income CAGR (Compound Annual Growth Rate)
1 Year
+6631.44%
3 Year
+64.02%
5 Year
+24.51%
10 Year
+40.17%
15 Year
+24.45%
20 Year
+24.45%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Net Income History
| Year | Net Income | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.29B | +$1.25B | +3844.96% |
| 2024 | $32.62M | ($564.98M) | (94.54%) |
| 2023 | $597.60M | +$256.94M | +75.42% |
| 2022 | $340.66M | ($607.92M) | (64.09%) |
| 2021 | $948.58M | +$1.24B | — |
| 2020 | ($295.70M) | ($742.60M) | (166.17%) |
| 2019 | $446.91M | +$337.41M | +308.16% |
| 2018 | $109.49M | +$422.63M | — |
| 2017 | ($313.14M) | ($417.36M) | (400.46%) |
| 2016 | $104.22M | +$97.69M | +1495.80% |
Net Income Growth Summary
TTM Growth
+6631.44%
3-Year Avg Growth
+64.02%
5-Year Avg Growth
+24.51%
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury